ClinicalTrials.gg
CompletedNCT04936035KARDIA-1Updated Dec 23, 2025Results posted

A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension

A Phase 2 interventional study of Placebo and ALN-AGT01 in Hypertension, sponsored by Alnylam Pharmaceuticals. Completed at 75 sites in 5 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2025-12-23.

Sponsored by Alnylam Pharmaceuticals · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
394
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 2,031 studies in Hypertension with a site in United States — 272 open to participants now, 369 under way, 16 of them phase 3. Hypertension · United States.

Enrollment
406th of 1,779
394 · median 100
Started
2021
with 95 others
Phase 2
170 of 2,031
21 open now
Registered
1,489th of 2,031
by date

Among the 2,031 studies in Hypertension with a site in United States, this one is the 406th largest by enrollment of the 1,779 interventional ones that give a count, is one of 96 that started in 2021, is one of 170 in phase 2, and was the 1,489th registered.

Hypertension

6,122 studies on the registry are indexed under Hypertension; 909 are open to participants now.

Browse Hypertension studies →

Open to participants now

272 of the 2,031 studies in Hypertension with a site in United States are open now. Recruiting first, the newest first:

267 more — sign in →

All 272 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 558 Hypertension studies recruiting now, 265 (47%) set no upper age limit and 197 (35%) stop at 75 or younger; 40 take children under 18; 139 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 2,031 studies in Hypertension with a site in United States, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the effect of ALN-AGT01 on systolic and diastolic blood pressure and to characterize the pharmacodynamic (PD) effects and safety of ALN-AGT01.

Read the detailed description

Participants will receive ALN-AGT01 or placebo for the first 6 months of the 12-month double-blind (DB) treatment period. Participants randomized to placebo will be re-randomized at Month 6 to 1 of the 4 initial ALN-AGT01 regimens until the end of the 12-month DB treatment period. Participants randomized to ALN-AGT01 regimens will remain on their originally assigned regimens through remainder of the study.

03

Conditions studied

  • Hypertension

Browse trials for

Keywords

  • High blood pressure
  • Hypertension
  • Hypertensive
  • siRNA
  • Angiotensinogen
  • AGT
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Daytime mean SBP ≥135 mmHg and ≤160 mmHg by ABPM, without antihypertensive medication

Exclusion criteria

Exclusion Criteria:

  • Secondary hypertension, orthostatic hypotension
  • (ALT) or aspartate aminotransferase (AST) >2× (ULN)
  • Elevated potassium >5 mEq/L
  • Estimated (eGFR) of ≤30 mL/min/1.73m\^2
  • Received an agent within the last 30 days
  • Type 1 diabetes mellitus, poorly controlled Type 2 diabetes mellitus, newly diagnosed Type 2 diabetes mellitus
  • History of any cardiovascular event within 6 months prior to randomization
  • History of intolerance to SC injection(s)
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
394 participants (actual)

Study arms

  • Placebo comparator
    Placebo

    Participants received zilebesiran matching placebo, subcutaneous (SC) injection, once every 3 months (Q3M), with re-randomization at Month 6 to 1 of the initial 4 zilebesiran regimens. Participants will continue their respective zilebesiran regimen up to Month 12 in the DB period and up to 24 additional months in the DB Extension period. Upon implementation of Amendment 6, the DB Extension period was closed.

    Drug: Placebo · Drug: ALN-AGT01

  • Experimental
    Zilebesiran 150 Milligrams (mg) Once Every 6 Months (Q6M)

    Participants receive zilebesiran, 150 mg, SC injection, Q6M, during the 12-month DB period. Participants will continue receiving the same zilebesiran regimen for up to 24 additional months in the DB Extension period. Participants in this arm will receive a placebo during those dosing visits when they do not receive zilebesiran to maintain the blind. Upon implementation of Amendment 6, the DB Extension period was closed.

    Drug: Placebo · Drug: ALN-AGT01

  • Experimental
    Zilebesiran 300 mg Q6M

    Participants receive zilebesiran, 300 mg, SC injection, Q6M, during the 12-month DB period. Participants will continue receiving the same zilebesiran regimen for up to 24 additional months in the DB Extension period. Participants in this arm will receive a placebo during those dosing visits when they do not receive zilebesiran to maintain the blind. Upon implementation of Amendment 6, the DB Extension period was closed.

    Drug: Placebo · Drug: ALN-AGT01

  • Experimental
    Zilebesiran 300 mg Q3M

    Participants receive zilebesiran, 300 mg, SC injection, Q3M, during the 12-month DB period. Participants continue receiving the same zilebesiran regimen for up to 24 additional months in the DB Extension period. Upon implementation of Amendment 6, the DB Extension period was closed.

    Drug: ALN-AGT01

  • Experimental
    Zilebesiran 600 mg Q6M

    Participants receive zilebesiran, 600 mg, SC injection, Q6M, during the 12-month DB period. Participants will continue receiving the same zilebesiran regimen for up to 24 additional months in the DB Extension period. Participants in this arm will receive a placebo during those dosing visits when they do not receive zilebesiran to maintain the blind. Upon implementation of Amendment 6, the DB Extension period was closed.

    Drug: Placebo · Drug: ALN-AGT01

Interventions

  • DrugPlacebo

    Placebo administered by SC injection

  • ALN-AGT01 administered by SC injection

    Also known as: Zilebesiran

06

What researchers measure

Primary outcomes

  1. Change From Baseline at Month 3 in 24-hour Mean SBP Assessed by ABPM

    24-hour ABPM was programmed to take readings every 20 minutes during the day (6 am to 9:59 pm) and every 30 minutes during the night (10 pm to 5:59 am). An ABPM was considered adequate if: 1. the number of successful daytime readings were ≥33, 2. the number of successful nighttime readings were ≥11, 3. no more than 3 hours are not represented (i.e., 3 sections of 60 minutes where 0 valid readings were obtained). To summarize the 24-hour ABPM, the hourly adjusted mean was calculated. Hourly mean was the average of BP by each hour of the day. The 24-hour mean was the average of the hourly means. Least squares (LS) mean and standard error (SE) were calculated using a mixed model repeated measures (MMRM) approach.

    Time frame: Baseline and Month 3

Secondary outcomes

  1. Change From Baseline at Month 3 in Mean Sitting Office SBP

    The mean office BP in the sitting position was used for the analysis. Office BP in the sitting position was collected with a set of 4 replicates. The average of the last 3 replicates was calculated and used for analysis. LS mean and SE were calculated using a MMRM approach.

    Time frame: Baseline and Month 3

  2. Change From Baseline at Month 6 in 24-hour Mean SBP Assessed by ABPM

    24-hour ABPM was programmed to take readings every 20 minutes during the day (6 am to 9:59 pm) and every 30 minutes during the night (10 pm to 5:59 am). An ABPM was considered adequate if: 1. the number of successful daytime readings were ≥33, 2. the number of successful nighttime readings were ≥11, 3. no more than 3 hours are not represented (i.e., 3 sections of 60 minutes where 0 valid readings were obtained). To summarize the 24-hour ABPM, the hourly adjusted mean was calculated. Hourly mean was the average of blood pressure (BP) by each hour of the day. The 24-hour mean was the average of the hourly means. LS mean and SE were calculated using a MMRM approach.

    Time frame: Baseline and Month 6

  3. Change From Baseline at Month 6 in Mean Sitting Office SBP

    The mean office BP in the sitting position was used for the analysis. Office BP in the sitting position was collected with a set of 4 replicates. The average of the last 3 replicates was calculated and used for analysis. LS mean and SE were calculated using a MMRM approach.

    Time frame: Baseline and Month 6

  4. Percentage of Participants With 24-hour Mean SBP Assessed by ABPM <130 mmHg and/or Reduction of ≥20 mmHg From Baseline Without Additional Antihypertensive Medications at Month 6

    24-hour ABPM was programmed to take readings every 20 minutes during the day (6 am to 9:59 pm) and every 30 minutes during the night (10 pm to 5:59 am). An ABPM was considered adequate if: 1. the number of successful daytime readings were ≥33, 2. the number of successful nighttime readings were ≥11, 3. no more than 3 hours are not represented (i.e., 3 sections of 60 minutes where 0 valid readings were obtained). To summarize the 24-hour ABPM, the hourly adjusted mean was calculated. Hourly mean was the average of blood pressure (BP) by each hour of the day. The 24-hour mean was the average of the hourly means.

    Time frame: Month 6

  5. Change From Baseline at Month 3 in 24-hour Mean DBP Assessed by ABPM

    24-hour ABPM was programmed to take readings every 20 minutes during the day (6 am to 9:59 pm) and every 30 minutes during the night (10 pm to 5:59 am). An ABPM was considered adequate if: 1. the number of successful daytime readings were ≥33, 2. the number of successful nighttime readings were ≥11, 3. no more than 3 hours are not represented (i.e., 3 sections of 60 minutes where 0 valid readings were obtained). To summarize the 24-hour ABPM, the hourly adjusted mean was calculated. Hourly mean was the average of blood pressure (BP) by each hour of the day. The 24-hour mean was the average of the hourly means. LS mean and SE were calculated using a MMRM approach.

    Time frame: Baseline and Month 3

  6. Change From Baseline at Month 6 in 24-hour Mean DBP Assessed by ABPM

    24-hour ABPM was programmed to take readings every 20 minutes during the day (6 am to 9:59 pm) and every 30 minutes during the night (10 pm to 5:59 am). An ABPM was considered adequate if: 1. the number of successful daytime readings were ≥33, 2. the number of successful nighttime readings were≥11, 3. no more than 3 hours are not represented (i.e., 3 sections of 60 minutes where 0 valid readings were obtained). To summarize the 24-hour ABPM, the hourly adjusted mean was calculated. Hourly mean was the average of blood pressure (BP) by each hour of the day. The 24-hour mean was the average of the hourly means. LS mean and SE were calculated using a MMRM approach

    Time frame: Baseline and Month 6

  7. Change From Baseline at Month 3 in Mean Sitting Office DBP

    The mean office BP in the sitting position was used for the analysis. Office BP in the sitting position was collected with a set of 4 replicates. The average of the last 3 replicates was calculated and used for analysis. LS mean and SE were calculated using a MMRM approach.

    Time frame: Baseline and Month 3

  8. Time Adjusted Change From Baseline Through Month 3 in Mean Sitting Office SBP and DBP

    Time adjusted change from baseline in mean sitting office SBP and DBP was the area under the curve (AUC) between Month 1 and 3 visits divided by the duration of time period.

    Time frame: Baseline and Month 3

  9. Change From Baseline at Month 6 in Mean Sitting Office DBP

    The mean office BP in the sitting position was used for the analysis. Office BP in the sitting position was collected with a set of 4 replicates. The average of the last 3 replicates was calculated and used for analysis. LS mean and SE were calculated using a MMRM approach.

    Time frame: Baseline and Month 6

  10. Time Adjusted Change From Baseline Through Month 6 in 24-hour Mean SBP and DBP Assessed by ABPM

    Time adjusted change from baseline through Month 6 in 24-hour mean SBP and DBP was determined as the AUC between Month 1 and 6 visits divided by the duration of the time period.

    Time frame: Baseline and Month 6

  11. Time Adjusted Change From Baseline Through Month 6 in Mean Sitting Office SBP and DBP

    Time adjusted change is the AUC between Month 1 and 6 visits divided by the duration of time period.

    Time frame: Baseline and Month 6

  12. Change From Baseline in Daytime/Nighttime Mean SBP and DBP Assessed by ABPM at Each Visit

    ABPM was programmed to take readings every 20 minutes during the day (6 am to 9:59 pm) and every 30 minutes during the night (10 pm to 5:59 am). An ABPM was considered adequate if: 1. the number of successful daytime readings were ≥33, 2. the number of successful nighttime readings were ≥11, and 3. no more than 3 hours are not represented (i.e., 3 sections of 60 minutes where 0 valid readings were obtained). Baseline was defined as the last assessment prior to receiving the first dose of study drug. LS mean and SE were calculated using a MMRM approach.

    Time frame: Baseline, and Months 1, 3 and 6

  13. Percentage Change From Baseline in Serum Angiotensinogen (AGT) Through Month 6

    Time frame: Baseline, Week 2 and Months 1, 2, 3, 4, 5 and 6

07

Results

Posted Dec 27, 2024

Participant flow

Total of 86 clinical sites across North America \& 25 sites in Europe enrolled 394 participants. 16 participants from Ukraine were unable to continue participation due to geopolitical instability. Due to challenges in data collection \& cleaning, these participants were excluded from all analysis sets. Hence, results are presented for 378 randomized participants. Study has 2 periods: 6-Month Placebo-controlled Double-blind (DB) Period \& Post-6-Month DB Period \[DB (Months 6 to 12)+DB Extension\].

6-Month Placebo-controlled DB Period
Participant flow — 6-Month Placebo-controlled DB Period
MilestonePlaceboZilebesiran 150 Milligrams (mg) Once Every 6 Months (Q6M)Zilebesiran 300 mg Q6MZilebesiran 300 mg Q3MZilebesiran 600 mg Q6MPlacebo/Zilebesiran 150 mg Q6MPlacebo/Zilebesiran 300 mg Q6MPlacebo/Zilebesiran 300 mg Q3MPlacebo/Zilebesiran 600 mg Q6MZilebesiran/Zilebesiran 150 mg Q6MZilebesiran/Zilebesiran 300 mg Q6MZilebesiran/Zilebesiran 300 mg Q3MZilebesiran/Zilebesiran 600 mg Q6M
Started767873757600000000
Completed707070707100000000
Not completed6835500000000
Withdrew: Adverse event0100000000000
Withdrew: Death0001000000000
Withdrew: Lost to follow-up0112100000000
Withdrew: Physician decision0100000000000
Withdrew: Protocol deviation0010000000000
Withdrew: Subject stopped participation in the study5512300000000
Withdrew: Reason unknown0000100000000
Withdrew: Withdrawal by subject1000000000000
Post-6-Month DB Period (30months)
Participant flow — Post-6-Month DB Period (30months)
MilestonePlaceboZilebesiran 150 Milligrams (mg) Once Every 6 Months (Q6M)Zilebesiran 300 mg Q6MZilebesiran 300 mg Q3MZilebesiran 600 mg Q6MPlacebo/Zilebesiran 150 mg Q6MPlacebo/Zilebesiran 300 mg Q6MPlacebo/Zilebesiran 300 mg Q3MPlacebo/Zilebesiran 600 mg Q6MZilebesiran/Zilebesiran 150 mg Q6MZilebesiran/Zilebesiran 300 mg Q6MZilebesiran/Zilebesiran 300 mg Q3MZilebesiran/Zilebesiran 600 mg Q6M
Started000001717161869676665
Completed month 12 visit000001316161865626561
Completed000001215151860575958
Not completed00000521091077
Withdrew: Participant stopped participation in the study0000021002753
Withdrew: Lost to follow-up0000011003114
Withdrew: Physician decision0000000002010
Withdrew: Adverse event0000010100000
Withdrew: Death0000000001000
Withdrew: Reason not specified0000010001200

Outcome measures

PrimaryChange From Baseline at Month 3 in 24-hour Mean SBP Assessed by ABPM

24-hour ABPM was programmed to take readings every 20 minutes during the day (6 am to 9:59 pm) and every 30 minutes during the night (10 pm to 5:59 am). An ABPM was considered adequate if: 1. the number of successful daytime readings were ≥33, 2. the number of successful nighttime readings were ≥11, 3. no more than 3 hours are not represented (i.e., 3 sections of 60 minutes where 0 valid readings were obtained). To summarize the 24-hour ABPM, the hourly adjusted mean was calculated. Hourly mean was the average of BP by each hour of the day. The 24-hour mean was the average of the hourly means. Least squares (LS) mean and standard error (SE) were calculated using a mixed model repeated measures (MMRM) approach.

Time frame:
Baseline and Month 3
Reported as:
Least squares mean · millimeters of mercury (mmHg)
Change From Baseline at Month 3 in 24-hour Mean SBP Assessed by ABPM
millimeters of mercury (mmHg)PlaceboZilebesiran 150 mg Q6MZilebesiran 300 mg Q6M and Q3MZilebesiran 600 mg Q6M
Change From Baseline at Month 3 in 24-hour Mean SBP Assessed by ABPM6.8 ± 1.58-7.3 ± 1.49-10.0 ± 1.05-8.9 ± 1.52
Statistical analysis
  • Placebo vs Zilebesiran 300 mg Q6M and Q3M · MMRM · p = <0.0001 (MMRM model included treatment, visit, treatment-by-visit interaction, and race (categorized as Black and all other races) as fixed factors, with baseline 24-hour mean SBP assessed by ABPM as a covariate.) · Difference in ls mean: -16.7 · 95% CI -21.2 to -12.3
  • Placebo vs Zilebesiran 600 mg Q6M · MMRM · p = <0.0001 (The MMRM model included treatment, visit, treatment-by-visit interaction, and race (categorized as Black and all other races) as fixed factors, with baseline 24-hour mean SBP assessed by ABPM as a covariate.) · Difference in ls mean: -15.7 · 95% CI -20.8 to -10.6
SecondaryChange From Baseline at Month 3 in Mean Sitting Office SBP

The mean office BP in the sitting position was used for the analysis. Office BP in the sitting position was collected with a set of 4 replicates. The average of the last 3 replicates was calculated and used for analysis. LS mean and SE were calculated using a MMRM approach.

Time frame:
Baseline and Month 3
Reported as:
Least squares mean · mmHg
Change From Baseline at Month 3 in Mean Sitting Office SBP
mmHgPlaceboZilebesiran 150 mg Q6MZilebesiran 300 mg Q6M and Q3MZilebesiran 600 mg Q6M
Change From Baseline at Month 3 in Mean Sitting Office SBP-0.1 ± 1.57-9.7 ± 1.49-12.1 ± 1.06-9.2 ± 1.52
Statistical analysis
  • Placebo vs Zilebesiran 300 mg Q6M and Q3M · MMRM · p = <0.0001 (The MMRM model included treatment, visit, treatment-by-visit interaction, and race (categorized as Black and all other races) as fixed factors, with office SBP as a covariate.) · Difference in ls mean: -12 · 95% CI -15.7 to -8.3Tested in hierarchical order with success criterion of nominal p-value \<0.05.
  • Placebo vs Zilebesiran 600 mg Q6M · MMRM · p = <0.0001 (The MMRM model included treatment, visit, treatment-by-visit interaction, and race (categorized as Black and all other races) as fixed factors, with office SBP as a covariate.) · Difference in ls mean: -9.1 · 95% CI -13.4 to -4.8Tested in hierarchical order with success criterion of nominal p-value \<0.05.
SecondaryChange From Baseline at Month 6 in 24-hour Mean SBP Assessed by ABPM

24-hour ABPM was programmed to take readings every 20 minutes during the day (6 am to 9:59 pm) and every 30 minutes during the night (10 pm to 5:59 am). An ABPM was considered adequate if: 1. the number of successful daytime readings were ≥33, 2. the number of successful nighttime readings were ≥11, 3. no more than 3 hours are not represented (i.e., 3 sections of 60 minutes where 0 valid readings were obtained). To summarize the 24-hour ABPM, the hourly adjusted mean was calculated. Hourly mean was the average of blood pressure (BP) by each hour of the day. The 24-hour mean was the average of the hourly means. LS mean and SE were calculated using a MMRM approach.

Time frame:
Baseline and Month 6
Reported as:
Least squares mean · mmHg
Change From Baseline at Month 6 in 24-hour Mean SBP Assessed by ABPM
mmHgPlaceboZilebesiran 150 mg Q6MZilebesiran 300 mg Q6MZilebesiran 300 mg Q3MZilebesiran 600 mg Q6M
Change From Baseline at Month 6 in 24-hour Mean SBP Assessed by ABPM4.6 ± 1.73-6.5 ± 1.63-9.9 ± 1.58-9.5 ± 1.65-9.6 ± 1.62
Statistical analysis
  • Placebo vs Zilebesiran 300 mg Q3M · MMRM · p = <0.0001 (The MMRM model included treatment, visit, treatment-by-visit interaction, and race (categorized as Black and all other races) as fixed factors, with baseline 24-hour mean SBP assessed by ABPM as a covariate.) · Difference in ls mean: -14.1 · 95% CI -18.9 to -9.4Tested in hierarchical order with success criterion of nominal p-value \<0.05.
  • Placebo vs Zilebesiran 600 mg Q6M · MMRM · p = <0.0001 (The MMRM model included treatment, visit, treatment-by-visit interaction, and race (categorized as Black and all other races) as fixed factors, with baseline 24-hour mean SBP assessed by ABPM as a covariate.) · Difference in ls mean: -14.2 · 95% CI -18.9 to -9.5Tested in hierarchical order with success criterion of nominal p-value \<0.05.
SecondaryChange From Baseline at Month 6 in Mean Sitting Office SBP

The mean office BP in the sitting position was used for the analysis. Office BP in the sitting position was collected with a set of 4 replicates. The average of the last 3 replicates was calculated and used for analysis. LS mean and SE were calculated using a MMRM approach.

Time frame:
Baseline and Month 6
Reported as:
Least squares mean · mmHg
Change From Baseline at Month 6 in Mean Sitting Office SBP
mmHgPlaceboZilebesiran 150 mg Q6MZilebesiran 300 mg Q6MZilebesiran 300 mg Q3MZilebesiran 600 mg Q6M
Change From Baseline at Month 6 in Mean Sitting Office SBP-0.6 ± 1.80-8.2 ± 1.70-11.1 ± 1.67-12.8 ± 1.80-10.8 ± 1.73
Statistical analysis
  • Placebo vs Zilebesiran 300 mg Q3M · MMRM · p = <0.0001 (The MMRM model included treatment, visit, treatment-by-visit interaction, and race (categorized as Black and all other races) as fixed factors, with office SBP as a covariate.) · Difference in ls mean: -12.1 · 95% CI -17.2 to -7.1Tested in hierarchical order with success criterion of nominal p-value \<0.05.
  • Placebo vs Zilebesiran 600 mg Q6M · MMRM · p = <0.0001 (The MMRM model included treatment, visit, treatment-by-visit interaction, and race (categorized as Black and all other races) as fixed factors, with office SBP as a covariate.) · Difference in ls mean: -10.2 · 95% CI -15.1 to -5.3Tested in hierarchical order with success criterion of nominal p-value \<0.05.
SecondaryPercentage of Participants With 24-hour Mean SBP Assessed by ABPM <130 mmHg and/or Reduction of ≥20 mmHg From Baseline Without Additional Antihypertensive Medications at Month 6

24-hour ABPM was programmed to take readings every 20 minutes during the day (6 am to 9:59 pm) and every 30 minutes during the night (10 pm to 5:59 am). An ABPM was considered adequate if: 1. the number of successful daytime readings were ≥33, 2. the number of successful nighttime readings were ≥11, 3. no more than 3 hours are not represented (i.e., 3 sections of 60 minutes where 0 valid readings were obtained). To summarize the 24-hour ABPM, the hourly adjusted mean was calculated. Hourly mean was the average of blood pressure (BP) by each hour of the day. The 24-hour mean was the average of the hourly means.

Time frame:
Month 6
Reported as:
Number · percentage of participants
Percentage of Participants With 24-hour Mean SBP Assessed by ABPM <130 mmHg and/or Reduction of ≥20 mmHg From Baseline Without Additional Antihypertensive Medications at Month 6
percentage of participantsPlaceboZilebesiran 150 mg Q6MZilebesiran 300 mg Q6MZilebesiran 300 mg Q3MZilebesiran 600 mg Q6M
Percentage of Participants With 24-hour Mean SBP Assessed by ABPM <130 mmHg and/or Reduction of ≥20 mmHg From Baseline Without Additional Antihypertensive Medications at Month 66.730.850.738.747.4
Statistical analysis
  • Placebo vs Zilebesiran 300 mg Q3M · Regression, Logistic · p = <0.0001 (Logistic regression model included treatment and race (black; all other races) as factors and baseline 24-hour mean SBP as a covariate) · Odds ratio (or): 10.73 · 95% CI 3.76 to 30.64Tested in hierarchical order with success criterion of nominal p-value \<0.05.
  • Placebo vs Zilebesiran 600 mg Q6M · Regression, Logistic · p = <0.0001 (Logistic regression model included treatment and race (black; all other races) as factors and baseline 24-hour mean SBP as a covariate) · Odds ratio (or): 17.93 · 95% CI 6.24 to 51.52Tested in hierarchical order with success criterion of nominal p-value \<0.05.
SecondaryChange From Baseline at Month 3 in 24-hour Mean DBP Assessed by ABPM

24-hour ABPM was programmed to take readings every 20 minutes during the day (6 am to 9:59 pm) and every 30 minutes during the night (10 pm to 5:59 am). An ABPM was considered adequate if: 1. the number of successful daytime readings were ≥33, 2. the number of successful nighttime readings were ≥11, 3. no more than 3 hours are not represented (i.e., 3 sections of 60 minutes where 0 valid readings were obtained). To summarize the 24-hour ABPM, the hourly adjusted mean was calculated. Hourly mean was the average of blood pressure (BP) by each hour of the day. The 24-hour mean was the average of the hourly means. LS mean and SE were calculated using a MMRM approach.

Time frame:
Baseline and Month 3
Reported as:
Least squares mean · mmHg
Change From Baseline at Month 3 in 24-hour Mean DBP Assessed by ABPM
mmHgPlaceboZilebesiran 150 mg Q6MZilebesiran 300 mg Q6M and Q3MZilebesiran 600 mg Q6M
Change From Baseline at Month 3 in 24-hour Mean DBP Assessed by ABPM3.5 ± 0.87-4.5 ± 0.82-5.7 ± 0.58-5.8 ± 0.84
SecondaryChange From Baseline at Month 6 in 24-hour Mean DBP Assessed by ABPM

24-hour ABPM was programmed to take readings every 20 minutes during the day (6 am to 9:59 pm) and every 30 minutes during the night (10 pm to 5:59 am). An ABPM was considered adequate if: 1. the number of successful daytime readings were ≥33, 2. the number of successful nighttime readings were≥11, 3. no more than 3 hours are not represented (i.e., 3 sections of 60 minutes where 0 valid readings were obtained). To summarize the 24-hour ABPM, the hourly adjusted mean was calculated. Hourly mean was the average of blood pressure (BP) by each hour of the day. The 24-hour mean was the average of the hourly means. LS mean and SE were calculated using a MMRM approach

Time frame:
Baseline and Month 6
Reported as:
Least squares mean · mmHg
Change From Baseline at Month 6 in 24-hour Mean DBP Assessed by ABPM
mmHgPlaceboZilebesiran 150 mg Q6MZilebesiran 300 mg Q6MZilebesiran 300 mg Q3MZilebesiran 600 mg Q6M
Change From Baseline at Month 6 in 24-hour Mean DBP Assessed by ABPM2.2 ± 0.97-4.8 ± 0.91-6.1 ± 0.89-6.3 ± 0.93-6.3 ± 0.91
SecondaryChange From Baseline at Month 3 in Mean Sitting Office DBP

The mean office BP in the sitting position was used for the analysis. Office BP in the sitting position was collected with a set of 4 replicates. The average of the last 3 replicates was calculated and used for analysis. LS mean and SE were calculated using a MMRM approach.

Time frame:
Baseline and Month 3
Reported as:
Least squares mean · mmHg
Change From Baseline at Month 3 in Mean Sitting Office DBP
mmHgPlaceboZilebesiran 150 mg Q6MZilebesiran 300 mg Q6M and Q3MZilebesiran 600 mg Q6M
Change From Baseline at Month 3 in Mean Sitting Office DBP-0.6 ± 1.00-5.3 ± 0.94-7.0 ± 0.67-5.4 ± 0.97
SecondaryTime Adjusted Change From Baseline Through Month 3 in Mean Sitting Office SBP and DBP

Time adjusted change from baseline in mean sitting office SBP and DBP was the area under the curve (AUC) between Month 1 and 3 visits divided by the duration of time period.

Time frame:
Baseline and Month 3
Reported as:
Least squares mean · mmHg
Time Adjusted Change From Baseline Through Month 3 in Mean Sitting Office SBP and DBP
mmHgPlaceboZilebesiran 150 mg Q6MZilebesiran 300 mg Q6M and Q3MZilebesiran 600 mg Q6M
Office SBP-0.6 ± 1.29-9.1 ± 1.24-10.9 ± 0.89-10.1 ± 1.26
Office DBP-0.0 ± 0.80-4.8 ± 0.77-6.5 ± 0.55-6.0 ± 0.78
SecondaryChange From Baseline at Month 6 in Mean Sitting Office DBP

The mean office BP in the sitting position was used for the analysis. Office BP in the sitting position was collected with a set of 4 replicates. The average of the last 3 replicates was calculated and used for analysis. LS mean and SE were calculated using a MMRM approach.

Time frame:
Baseline and Month 6
Reported as:
Least squares mean · mmHg
Change From Baseline at Month 6 in Mean Sitting Office DBP
mmHgPlaceboZilebesiran 150 mg Q6MZilebesiran 300 mg Q6MZilebesiran 300 mg Q3MZilebesiran 600 mg Q6M
Change From Baseline at Month 6 in Mean Sitting Office DBP-1.2 ± 1.20-4.1 ± 1.13-6.8 ± 1.12-8.2 ± 1.20-5.0 ± 1.16
SecondaryTime Adjusted Change From Baseline Through Month 6 in 24-hour Mean SBP and DBP Assessed by ABPM

Time adjusted change from baseline through Month 6 in 24-hour mean SBP and DBP was determined as the AUC between Month 1 and 6 visits divided by the duration of the time period.

Time frame:
Baseline and Month 6
Reported as:
Least squares mean · mmHg
Time Adjusted Change From Baseline Through Month 6 in 24-hour Mean SBP and DBP Assessed by ABPM
mmHgPlaceboZilebesiran 150 mg Q6MZilebesiran 300 mg Q6MZilebesiran 300 mg Q3MZilebesiran 600 mg Q6M
24-hour Mean SBP5.8 ± 1.26-6.3 ± 1.20-9.2 ± 1.20-9.6 ± 1.22-9.1 ± 1.22
24-hour Mean DBP3.1 ± 0.72-4.2 ± 0.69-5.5 ± 0.69-5.8 ± 0.70-5.9 ± 0.70
SecondaryTime Adjusted Change From Baseline Through Month 6 in Mean Sitting Office SBP and DBP

Time adjusted change is the AUC between Month 1 and 6 visits divided by the duration of time period.

Time frame:
Baseline and Month 6
Reported as:
Least squares mean · mmHg
Time Adjusted Change From Baseline Through Month 6 in Mean Sitting Office SBP and DBP
mmHgPlaceboZilebesiran 150 mg Q6MZilebesiran 300 mg Q6MZilebesiran 300 mg Q3MZilebesiran 600 mg Q6M
Office SBP-0.5 ± 1.25-9.0 ± 1.20-12.1 ± 1.21-11.0 ± 1.24-10.0 ± 1.22
Office DBP-0.6 ± 0.80-4.7 ± 0.76-7.2 ± 0.77-6.7 ± 0.79-5.5 ± 0.78
SecondaryChange From Baseline in Daytime/Nighttime Mean SBP and DBP Assessed by ABPM at Each Visit

ABPM was programmed to take readings every 20 minutes during the day (6 am to 9:59 pm) and every 30 minutes during the night (10 pm to 5:59 am). An ABPM was considered adequate if: 1. the number of successful daytime readings were ≥33, 2. the number of successful nighttime readings were ≥11, and 3. no more than 3 hours are not represented (i.e., 3 sections of 60 minutes where 0 valid readings were obtained). Baseline was defined as the last assessment prior to receiving the first dose of study drug. LS mean and SE were calculated using a MMRM approach.

Time frame:
Baseline, and Months 1, 3 and 6
Reported as:
Least squares mean · mmHg
Change From Baseline in Daytime/Nighttime Mean SBP and DBP Assessed by ABPM at Each Visit
mmHgPlaceboZilebesiran 150 mg Q6MZilebesiran 300 mg Q6MZilebesiran 300 mg Q3MZilebesiran 600 mg Q6M
Change in Daytime Mean SBP at Month 14.3 ± 1.50-3.6 ± 1.45-6.4 ± 1.51-9.6 ± 1.46-9.1 ± 1.48
Change in Daytime Mean SBP at Month 36.7 ± 1.62-7.6 ± 1.53-10.7 ± 1.52-9.8 ± 1.54-8.9 ± 1.56
Change in Daytime Mean SBP at Month 64.5 ± 1.83-6.9 ± 1.72-10.4 ± 1.66-9.3 ± 1.74-8.8 ± 1.71
Change in Nighttime Mean SBP at Month 14.7 ± 1.64-3.4 ± 1.59-5.1 ± 1.64-9.5 ± 1.60-8.0 ± 1.62
Change in Nighttime Mean SBP at Month 37.0 ± 1.85-6.4 ± 1.76-8.2 ± 1.74-9.7 ± 1.77-8.5 ± 1.79
Change in Nighttime Mean SBP at Month 64.7 ± 1.86-5.8 ± 1.75-8.9 ± 1.69-10.2 ± 1.78-11.1 ± 1.74
Change in Daytime Mean DBP at Month 12.9 ± 0.91-2.7 ± 0.88-4.0 ± 0.91-5.9 ± 0.89-5.8 ± 0.89
Change in Daytime Mean DBP at Month 33.5 ± 0.94-4.8 ± 0.89-6.1 ± 0.88-5.7 ± 0.90-5.6 ± 0.90
Change in Daytime Mean DBP at Month 62.1 ± 1.07-4.8 ± 1.01-6.2 ± 0.98-6.1 ± 1.02-5.7 ± 1.00
Change in Nighttime Mean DBP at Month 13.2 ± 1.01-2.4 ± 0.98-3.5 ± 1.02-5.9 ± 0.99-5.4 ± 1.00
Change in Nighttime Mean DBP at Month 33.7 ± 1.08-3.6 ± 1.02-5.1 ± 1.01-4.8 ± 1.03-5.8 ± 1.04
Change in Nighttime Mean DBP at Month 62.2 ± 1.09-4.3 ± 1.03-5.9 ± 1.00-6.7 ± 1.05-7.6 ± 1.03
SecondaryPercentage Change From Baseline in Serum Angiotensinogen (AGT) Through Month 6
Time frame:
Baseline, Week 2 and Months 1, 2, 3, 4, 5 and 6
Reported as:
Mean · percent change
Percentage Change From Baseline in Serum Angiotensinogen (AGT) Through Month 6
percent changePlaceboZilebesiran 150 mg Q6MZilebesiran 300 mg Q6MZilebesiran 300 mg Q3MZilebesiran 600 mg Q6M
Percent Change from Baseline at Week 2-0.05 ± 23.99-88.34 ± 9.96-92.68 ± 4.40-92.77 ± 4.03-94.49 ± 5.52
Percent Change from Baseline at Month 11.61 ± 22.96-94.48 ± 9.04-97.38 ± 1.72-97.20 ± 2.30-98.22 ± 2.69
Percent Change from Baseline at Month 2-2.06 ± 21.87-94.47 ± 12.38-97.74 ± 2.04-97.64 ± 2.15-98.70 ± 0.74
Percent Change from Baseline at Month 3-2.19 ± 22.86-93.31 ± 9.94-97.26 ± 2.78-97.00 ± 2.61-98.25 ± 1.60
Percent Change from Baseline at Month 41.39 ± 26.06-91.89 ± 11.61-95.94 ± 5.23-98.38 ± 1.08-97.98 ± 1.74
Percent Change from Baseline at Month 5-2.27 ± 21.18-90.10 ± 12.48-94.85 ± 6.58-98.23 ± 1.13-97.38 ± 2.41
Percent Change from Baseline at Month 6-4.97 ± 24.90-87.84 ± 13.82-93.13 ± 8.29-97.71 ± 1.91-96.41 ± 4.04

Adverse events

Collected over 6-Month Placebo-controlled DB Period: Day1 up to Month 6; Post-6-Month DB Period: Pbo/Zil arms: From first zilebesiran dose (Month 6) up to Month 36; Zil/ Zil: From first zilebesiran dose (Day 1) up to Month 36 Placebo-controlled DB: Safety Analysis Set=all participants who received any amount of study drug, grouped per treatment received. As planned, AEs were reported for Zilebesiran Treatment Period using All Zilebesiran Treated Set showing data by treatment sequence (Pbo/Zil & Zil/Zil).. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo0/75 (0%)5/75 (6.7%)18/75 (24%)
Zilebesiran 150 mg Q6M0/78 (0%)0/78 (0%)21/78 (26.9%)
Zilebesiran 300 mg Q6M0/73 (0%)1/73 (1.4%)24/73 (32.9%)
Zilebesiran 300 mg Q3M1/75 (1.3%)4/75 (5.3%)23/75 (30.7%)
Zilebesiran 600 mg Q6M0/76 (0%)6/76 (7.9%)20/76 (26.3%)
Placebo/Zilebesiran 150 mg Q6M0/16 (0%)1/16 (6.3%)9/16 (56.3%)
Placebo/Zilebesiran 300 mg Q6M0/16 (0%)0/16 (0%)12/16 (75%)
Placebo/Zilebesiran 300 mg Q3M0/16 (0%)1/16 (6.3%)9/16 (56.3%)
Placebo/Zilebesiran 600 mg Q6M0/18 (0%)0/18 (0%)8/18 (44.4%)
Zilebesiran/Zilebesiran 150 mg Q6M1/78 (1.3%)5/78 (6.4%)53/78 (67.9%)
Zilebesiran/Zilebesiran 300 mg Q6M0/73 (0%)5/73 (6.8%)47/73 (64.4%)
Zilebesiran/Zilebesiran 300 mg Q3M1/75 (1.3%)7/75 (9.3%)49/75 (65.3%)
Zilebesiran/ Zilebesiran 600 mg Q6M0/76 (0%)9/76 (11.8%)49/76 (64.5%)
Most frequent serious events
Showing 10 of 38
Most frequent serious events
EventPlaceboZilebesiran 150 mg Q6MZilebesiran 300 mg Q6MZilebesiran 300 mg Q3MZilebesiran 600 mg Q6MPlacebo/Zilebesiran 150 mg Q6MPlacebo/Zilebesiran 300 mg Q6MPlacebo/Zilebesiran 300 mg Q3MPlacebo/Zilebesiran 600 mg Q6MZilebesiran/Zilebesiran 150 mg Q6MZilebesiran/Zilebesiran 300 mg Q6MZilebesiran/Zilebesiran 300 mg Q3MZilebesiran/ Zilebesiran 600 mg Q6M
UrosepsisInfections and infestations0/750/780/730/750/760/160/161/160/180/780/730/751/76
Alanine aminotransferase increasedInvestigations0/750/780/730/750/761/160/160/160/180/780/730/750/76
Aspartate aminotransferase increasedInvestigations0/750/780/730/750/761/160/160/160/180/780/730/750/76
Acute kidney injuryRenal and urinary disorders0/750/780/730/750/760/160/161/160/181/780/730/750/76
Duodenal ulcer haemorrhageGastrointestinal disorders0/750/781/730/750/760/160/160/160/180/781/730/750/76
FallInjury, poisoning and procedural complications0/750/780/730/750/760/160/160/160/181/781/730/750/76
OsteoarthritisMusculoskeletal and connective tissue disorders0/750/780/730/750/760/160/160/160/180/781/730/750/76
Paraganglion neoplasmNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/750/780/730/750/760/160/160/160/180/781/730/750/76
SyncopeNervous system disorders0/750/780/730/750/760/160/160/160/181/781/730/750/76
Acute coronary syndromeCardiac disorders0/750/780/731/750/760/160/160/160/180/780/731/750/76
Most frequent other events
Showing 10 of 78
Most frequent other events
EventPlaceboZilebesiran 150 mg Q6MZilebesiran 300 mg Q6MZilebesiran 300 mg Q3MZilebesiran 600 mg Q6MPlacebo/Zilebesiran 150 mg Q6MPlacebo/Zilebesiran 300 mg Q6MPlacebo/Zilebesiran 300 mg Q3MPlacebo/Zilebesiran 600 mg Q6MZilebesiran/Zilebesiran 150 mg Q6MZilebesiran/Zilebesiran 300 mg Q6MZilebesiran/Zilebesiran 300 mg Q3MZilebesiran/ Zilebesiran 600 mg Q6M
Injection site reactionGeneral disorders0/753/784/738/754/760/163/161/161/185/788/7313/759/76
Urinary tract infectionInfections and infestations0/750/780/730/750/761/160/163/161/183/785/739/753/76
DiarrhoeaGastrointestinal disorders0/750/780/730/750/762/160/160/160/181/782/733/751/76
Upper respiratory tract infectionInfections and infestations1/753/784/732/751/762/160/161/161/186/785/736/754/76
Back painMusculoskeletal and connective tissue disorders0/750/780/730/750/760/162/160/160/182/783/733/752/76
HypotensionVascular disorders0/750/780/730/750/760/160/162/160/182/781/732/752/76
Coronavirus Disease of 2019 (COVID-19)Infections and infestations3/753/786/736/754/760/161/160/160/187/787/739/758/76
HypertensionVascular disorders5/754/780/733/755/761/160/161/160/189/783/734/759/76
ArthralgiaMusculoskeletal and connective tissue disorders2/752/784/732/750/760/160/160/162/183/786/734/750/76
DizzinessNervous system disorders4/752/782/733/753/760/160/160/161/183/783/734/758/76

Baseline characteristics

The Full Analysis Set included all randomized participants who received any amount of the study drug.

Age, Continuous
Age, Continuous(years)PlaceboZilebesiran 150 mg Q6MZilebesiran 300 mg Q6MZilebesiran 300 mg Q3MZilebesiran 600 mg Q6MTotal
Mean56.8 ± 11.255.5 ± 10.656.4 ± 10.357.7 ± 10.657.4 ± 10.256.8 ± 10.6
Sex: Female, Male
Sex: Female, Male(Participants)PlaceboZilebesiran 150 mg Q6MZilebesiran 300 mg Q6MZilebesiran 300 mg Q3MZilebesiran 600 mg Q6MTotal
Female3839293031167
Male3739444545210
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)PlaceboZilebesiran 150 mg Q6MZilebesiran 300 mg Q6MZilebesiran 300 mg Q3MZilebesiran 600 mg Q6MTotal
Hispanic or Latino91916102074
Not Hispanic or Latino6659576556303
Unknown or Not Reported000000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)PlaceboZilebesiran 150 mg Q6MZilebesiran 300 mg Q6MZilebesiran 300 mg Q3MZilebesiran 600 mg Q6MTotal
American Indian or Alaska Native010001
Asian5427523
Native Hawaiian or Other Pacific Islander000101
Black or African American182017191993
White5253544852259
More than one race000000
Unknown or Not Reported000000
24-hour Mean Systolic Blood Pressure (SBP) Assessed by Ambulatory Blood Pressure Monitoring (ABPM)
24-hour Mean Systolic Blood Pressure (SBP) Assessed by Ambulatory Blood Pressure Monitoring (ABPM)(millimeter of mercury (mmHg))PlaceboZilebesiran 150 mg Q6MZilebesiran 300 mg Q6MZilebesiran 300 mg Q3MZilebesiran 600 mg Q6MTotal
Mean141.1 ± 7.9140.6 ± 8.5142.5 ± 8.8141.6 ± 7.7143.1 ± 9.0141.8 ± 8.4
08

Study locations

75 sites
  • Clinical Trial Site
    Birmingham, Alabama 35209, United States
  • Clinical Trial Site
    Tempe, Arizona 85281, United States
  • Clinical Trial Site
    Tempe, Arizona 85282, United States
  • Clinical Trial Site
    Beverly Hills, California 90211, United States
  • Clinical Trial Site
    La Mesa, California 91942, United States
  • Clinical Trial Site
    Los Angeles, California 90057, United States
  • Clinical Trial Site
    San Diego, California 92103, United States
  • Clinical Trial Site
    South Gate, California 90280, United States
  • Clinical Trial Site
    Vista, California 92083, United States
  • Clinical Trial Site
    Washington D.C., District of Columbia 20011, United States
  • Clinical Trial Site
    Clearwater, Florida 33756, United States
  • Clinical Trial Site
    Coral Gables, Florida 33134, United States
  • Clinical Trial Site
    Fleming Island, Florida 32003, United States
  • Clinical Trial Site
    Hollywood, Florida 33021, United States
  • Clinical Trial Site
    Hollywood, Florida 33024, United States
  • Clinical Trial Site
    Inverness, Florida 34452, United States
  • Clinical Trial Site
    Jacksonville, Florida 32204, United States
  • Clinical Trial Site
    Jacksonville, Florida 32216, United States
  • Clinical Trial Site
    Jacksonville, Florida 32256, United States
  • Clinical Trial Site
    Miami, Florida 33126, United States
  • Clinical Trial Site
    Miami, Florida 33135, United States
  • Clinical Trial Site
    Naples, Florida 34102, United States
  • Clinical Trial Site
    Orlando, Florida 32801, United States
  • Clinical Trial Site
    Acworth, Georgia 30101, United States
  • Clinical Trial Site
    Columbus, Georgia 31904, United States
  • Clinical Trial Site
    Fayetteville, Georgia 30214, United States
  • Clinical Trial Site
    Macon, Georgia 31210, United States
  • Clinical Trial Site
    Champaign, Illinois 61822, United States
  • Clinical Trial Site
    Valparaiso, Indiana 46383, United States
  • Clinical Trial Site
    West Des Moines, Iowa 50266, United States
  • Clinical Trial Site
    Lake Charles, Louisiana 70601, United States
  • Clinical Trial Site
    New Orleans, Louisiana 70124, United States
  • Clinical Trial Site
    Prairieville, Louisiana 70769, United States
  • Clinical Trial Site
    Baltimore, Maryland 21229, United States
  • Clinical Trial Site
    Jackson, Mississippi 39209, United States
  • Clinical Trial Site
    Jefferson City, Missouri 65109, United States
  • Clinical Trial Site
    Las Vegas, Nevada 89119, United States
  • Clinical Trial Site
    New York, New York 10036, United States
  • Clinical Trial Site
    The Bronx, New York 10456, United States
  • Clinical Trial Site
    Greensboro, North Carolina 27408, United States
  • Clinical Trial Site
    Greensboro, North Carolina 27410, United States
  • Clinical Trial Site
    Medford, Oregon 97504, United States
  • Clinical Trial Site
    Greenville, South Carolina 29607, United States
  • Clinical Trial Site
    Memphis, Tennessee 38119, United States
  • Clinical Trial Site
    Cedar Park, Texas 78613, United States
  • Clinical Trial Site
    Houston, Texas 77074, United States
  • Clinical Trial Site
    Houston, Texas 77081, United States
  • Clinical Trial Site
    Magnolia, Texas 77355, United States
  • Clinical Trial Site
    Pearland, Texas 77584, United States
  • Clinical Trial Site
    San Antonio, Texas 78229, United States
  • Clinical Trial Site
    Stephenville, Texas 76401, United States
  • Clinical Trial Site
    Tomball, Texas 77375, United States
  • Clinical Trial Site
    Waco, Texas 76708, United States
  • Clinical Trial Site
    Burke, Virginia 22015, United States
  • Clinical Trial Site
    Red Deer, Alberta, Canada
  • Clinical Trial Site
    New Minas, Nova Scotia, Canada
  • Clinical Trial Site
    Brampton, Ontario, Canada
  • Clinical Trial Site
    Toronto, Ontario, Canada
  • Clinical Trial Site
    Chicoutimi, Quebec, Canada
  • Clinical Trial Site
    Mirabel, Quebec, Canada
  • Clinical Trial Site
    Montreal, Quebec, Canada
  • Clinical Trial Site
    Québec, Quebec, Canada
  • Clinical Trial Site
    Trois-Rivières, Quebec, Canada
  • Clinical Trial Site
    Victoriaville, Quebec, Canada
  • Clinical Trial Site
    Bayamón, 00961, Puerto Rico
  • Clinical Trial Site
    Ponce, 00716, Puerto Rico
  • Clinical Trial Site
    San Juan, Puerto Rico
  • Clinical Trial Site
    Ivano-Frankivsk, Ukraine
  • Clinical Trial Site
    Kharkiv, Ukraine
  • Clinical Trial Site
    Odesa, Ukraine
  • Clinical Trial Site
    Uzhhorod, Ukraine
  • Clinical Trial Site
    Glasgow, United Kingdom
  • Clinical Trial Site
    Hexham, United Kingdom
  • Clinical Trial Site
    London, United Kingdom
  • Clinical Trial Site
    Manchester, United Kingdom
09

References and documents

Publications

  • Bakris GL, Saxena M, Gupta A, Chalhoub F, Lee J, Stiglitz D, Makarova N, Goyal N, Guo W, Zappe D, Desai AS; KARDIA-1 Study Group. RNA Interference With Zilebesiran for Mild to Moderate Hypertension: The KARDIA-1 Randomized Clinical Trial. JAMA. 2024 Mar 5;331(9):740-749. doi: 10.1001/jama.2024.0728. PubMed 38363577 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Access to Anonymized individual participant data that support these results is made available 12 months after study completion and not less than 12 months after the product and indication have been approved in the US and/or the EU. Data will be provided contingent upon the approval of a research proposal and the execution of a data sharing agreement. Requests for access to data can be submitted via the website www.vivli.org.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2021 to primary completion in Apr 2023, 20 months.

Results were first posted in Dec 2024, 1 year 8 months after primary completion. A results delay was requested in Feb 2024.

Of 56 industry-sponsored phase 2 interventional studies under Hypertension, half reached primary completion within 14 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 22. This study's 20 months is above that.

Counting every sponsor, half of 110 studies reached it within 25 months; a quarter within 11 and three quarters within 56.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 14, 2021
First posted
Jun 23, 2021
StartActual
Jul 7, 2021
Primary completionActual
Apr 4, 2023
CompletionActual
Dec 5, 2024
Results delay requested
Feb 15, 2024
Results first posted
Dec 27, 2024
Last update
Dec 23, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 23, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04936035
Responsible party
Sponsor
First posted
Jun 23, 2021
Start date
Jul 7, 2021
Primary completion
Apr 4, 2023
Completion
Dec 5, 2024
Results posted
Dec 27, 2024
Last update
Dec 23, 2025

Study contacts

Medical Director
study director · Alnylam Pharmaceuticals

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Zilebesiran

Start the discussion